FAM83A drives PD-L1 expression via ERK signaling and FAM83A/PD-L1 co-expression correlates with poor prognosis in lung adenocarcinoma

[1] Garon EB(2015)Pembrolizumab for the treatment of non-small-cell lung cancer N Engl J Med 372 2018-2028

[2] Rizvi NA(2010)Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer N Engl J Med 363 1693-1703

[3] Hui R(2012)ROS1 rearrangements define a unique molecular class of lung cancers J Clin Oncol 30 863-870

[4] Kwak EL(2013)Responsetocabozantinibin patients with RET fusion-positive lung adenocarcinomas Cancer Discov 3 630-635

[5] Bang YJ(2004)Lung cancer: intragenic ERBB2 kinase mutations in tumours Nature 431 525-526

[6] Camidge DR(2016)Cancer statistics for African Americans, 2016: progress and opportunities in reducing racial disparities CA Cancer J Clin 66 290-308

[7] Bergethon K(2008)Lung cancer N Engl J Med 359 1367-1380

[8] Shaw AT(2012)The blockade of immune checkpoints in cancer immunotherapy Nat Rev Cancer 12 252-264

[9] Ou SH(2015)Nivolumab versus docetaxel in advanced nonsquamous non–small-cell lung cancer N Engl J Med 373 1627-1639

[10] Alexander D(2015)Nivolumab versus docetaxel in advanced squamous-cell nonsmall-cell lung cancer N Engl J Med 373 123-135

[1] Garon EB(2015)Pembrolizumab for the treatment of non-small-cell lung cancer N Engl J Med 372 2018-2028

[2] Rizvi NA(2010)Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer N Engl J Med 363 1693-1703

[3] Hui R(2012)ROS1 rearrangements define a unique molecular class of lung cancers J Clin Oncol 30 863-870

[4] Kwak EL(2013)Responsetocabozantinibin patients with RET fusion-positive lung adenocarcinomas Cancer Discov 3 630-635

[5] Bang YJ(2004)Lung cancer: intragenic ERBB2 kinase mutations in tumours Nature 431 525-526

[6] Camidge DR(2016)Cancer statistics for African Americans, 2016: progress and opportunities in reducing racial disparities CA Cancer J Clin 66 290-308

[7] Bergethon K(2008)Lung cancer N Engl J Med 359 1367-1380

[8] Shaw AT(2012)The blockade of immune checkpoints in cancer immunotherapy Nat Rev Cancer 12 252-264

[9] Ou SH(2015)Nivolumab versus docetaxel in advanced nonsquamous non–small-cell lung cancer N Engl J Med 373 1627-1639

[10] Alexander D(2015)Nivolumab versus docetaxel in advanced squamous-cell nonsmall-cell lung cancer N Engl J Med 373 123-135